Research is often lauded for finding life-saving treatments for diseases like cancer or diabetes. But consider the impact of preventing such illnesses from developing in the first place. It’s hard to describe the value of stopping illness or injury from happening. Yet that’s the goal of research on preventive care.
Most Kaiser Permanente Washington scientists study prevention, whether their work focuses on promoting health by influencing individual behavior, building sound prevention services into everyday clinical care, designing smart health coverage, or all three. By conducting their research at Kaiser Permanente Washington—which combines care and coverage—our researchers have access to data from a large, stable population over time, allowing them to discover which approaches to prevention work best.
Examples include research in areas such as:
A team of researchers at Kaiser Permanente Washington Health Research Institute (KPWHRI) produces reviews of scientific evidence that policymakers at the Centers for Medicare & Medicaid Services and the U.S. Preventive Services Task Force and others use in health care decision-making. We do this work as part of the Kaiser Permanente Research Affiliates Evidence-based Practice Center, one of 13 centers nationwide that are sponsored by the federal Agency for Healthcare Research and Quality.
We’re improving the safety and effectiveness of vaccines through clinical trials, and we’re monitoring how well each year’s new flu vaccines are working. In addition, we’re studying ways to better inform parents about the benefits and potential harms of childhood vaccines, to improve their uptake.
We’re working on several fronts to help ensure the safety of prescription drugs and other medical treatments. For example, we play a leading role in the Food and Drug Administration’s Sentinel program to monitor the safety of medical products through routinely collected electronic health care data. We’re exploring ways to improve the safety of prescribing opioid pain medications. And we often study the safety of drugs commonly used to prevent chronic conditions like heart disease, cancer, and depression.
Prevention also includes screening to detect disease before symptoms appear, to identify and treat disease at an earlier stage. Our research is improving the effectiveness of cancer screening programs so people get the appropriate tests when needed based on their particular risks. Our research is also aimed at improving clinical screening for behavioral risks such as smoking, suicidal thoughts, alcohol use disorders, and poor eating and exercise habits.
Our research in areas such as smoking cessation, healthy diet, and chronic illness care finds new ways to encourage individuals to adopt and maintain healthier lifestyles. At the same time, we’re exploring ways to reach large populations through the use of phone-based programs, websites, and mobile technologies.
Ryan ED, Chang YM, Oliver M, Bradley KA, Hallgren KA An Alcohol Symptom Checklist identifies high rates of alcohol use disorder in primary care patients who screen positive for depression and high-risk drinking 2022 Sep 5;22(1):1123. doi: 10.1186/s12913-022-08408-1. Epub 2022-09-05. PubMed
Karnik NS, Marsden J, McCluskey C, Boley RA, Bradley KA, Campbell CI, Curtis ME, Fiellin D, Ghitza U, Hefner K, Hser YI, McHugh RK, McPherson SM, Mooney LJ, Moran LM, Murphy SM, Schwartz RP, Shmueli-Blumberg D, Shulman M, Stephens KA, Watkins KE, Weiss RD, Wu LT The Opioid Use Disorder Core Outcomes Set (OUD-COS) for treatment research: findings from a Delphi consensus study 2022 Sep;117(9):2438-2447. doi: 10.1111/add.15875. Epub 2022-03-16. PubMed
Tilhou AS, Glass JE, Hetzel SJ, Shana OE, Borza T, Baltes A, Deyo BMF, Agarwal S, O'Rourke A, Brown RT Association between spine injury and opioid misuse in a prospective cohort of Level I trauma patients 2022 Sep;5(3). doi: 10.1097/OI9.0000000000000205. Epub 2022-07-12. PubMed
Scherrer JF, Salas J, Miller-Matero LR, Sullivan MD, Ballantyne JC, Debar L, Grucza RA, Lustman PJ, Ahmedani B Long-term prescription opioid users' risk for new onset depression increases with frequency of use 2022 Aug;163(8):1581-1589. doi: 10.1097/j.pain.0000000000002547. Epub 2021-11-30. PubMed
Frost MC, Richards JE, Blosnich JR, Hawkins EJ, Tsui JI, Edelman EJ, Williams EC Association between clinically recognized suicidality and subsequent initiation or continuation of medications for opioid use disorder 2022 Aug;237:109521. doi: 10.1016/j.drugalcdep.2022.109521. Epub 2022-06-03. PubMed
Julie Angerhofer, PhD, MPHAssociate Investigator |
Jennifer F. Bobb, PhDSenior Biostatistics Investigator |
Katharine A. Bradley, MD, MPHSenior Investigator |
Clarissa Hsu, PhDAssociate Investigator |
Noorie Hyun, PhDAssociate Biostatistics Investigator |
Morgan Justice, PhD, MASenior Collaborative Scientist |
Gwen Lapham, PhD, MPH, MSWAssociate Investigator |
Theresa E. Matson, PhD, MPHCollaborative Scientist |
Jess Mogk, MPHCollaborative Scientist |
Yu-Ru Su, PhDAssociate Biostatistics Investigator |
Paige D. Wartko, PhD, MPHSenior Collaborative Scientist |